AU - Talathi, Abhay AU - Talathi, Prajakta AU - Kapadia Rachh, Jalpa AU - Khan, Kaleem AU - Dhoot, Dhiraj AU - Deshmukh, Gaurav TI - Bilastine in pruritus associated with dermatological conditions PT - ORIG DP - 2022 Jul 1 TA - Indian Journal of Drugs in Dermatology PG - 59-65 VI - 8 IP - 2 4099- https://www.ijdd.in/article.asp?issn=2455-3972;year=2022;volume=8;issue=2;spage=59;epage=65;aulast=Talathi;type=0 4100- https://www.ijdd.in/article.asp?issn=2455-3972;year=2022;volume=8;issue=2;spage=59;epage=65;aulast=Talathi AB - Introduction: Pruritus is a common and unpleasant symptom associated with multiple skin diseases. As histamine plays a central role in pruritus pathology, H1 antihistamines are frequently used in its management. Bilastine is a potent second-generation antihistamine approved for the management of urticaria. However, there are few studies showing its effectiveness and safety in pruritus associated with skin diseases. Materials and Methods: In this multicenter, open-label study, patients with pruritus associated with various skin diseases received bilastine 20 mg once daily for 4 weeks. Patients were evaluated for improvement in their pruritus based on the 5D itch score and Dermatology Life Quality Index (DLQI). Safety of bilastine was assessed by monitoring the incidence of adverse events during the study period. Results: A total of 116 patients with urticaria (n = 22), eczema/dermatitis (n = 27), lichen planus (n = 9), pPsoriasis (n = 11), dermatophytosis (n = 42), and others (n = 5) were included in the study. There was a significant improvement in the 5D itch score at the end of therapy (16.18 ± 2.81 vs. 6.20 ± 1.38 P < 0.0001) in all patients. Bilastine improved the DLQI at week 4 in all disease groups (11.83 ± 4.97 vs. 2.15 ± 2.68; P < 0.0001). The treatment was well tolerated. Conclusion: Bilastine is associated with significant improvement in pruritus associated with multiple dermatological disorders with a very good safety profile.